Sun Pharma Sparks Market Rally on NSE After Mega $11.75 Billion Organon Acquisition, Marking Historic Pharma Deal

In a landmark move for India’s pharmaceutical sector, Sun Pharmaceutical Industries has announced the acquisition of U.S.-based Organon & Co. in an all-cash deal valued at $11.75 billion, marking the largest overseas acquisition ever undertaken by an Indian drugmaker. The deal underscores Sun Pharma’s aggressive global expansion strategy and its ambition to strengthen its position in high-value therapeutic segments.

Under the terms of the agreement, Sun Pharma will acquire all outstanding shares of Organon at a fixed price per share, with the transaction expected to close by early 2027, subject to regulatory approvals and shareholder consent. The acquisition is set to significantly expand Sun Pharma’s global footprint, particularly in developed markets such as the United States and Europe.

Organon brings with it a diversified portfolio of more than 70 products spanning women’s health, biosimilars, and established medicines, with a commercial presence in over 140 countries. This portfolio is expected to complement Sun Pharma’s existing strengths in specialty and generic medicines, while opening new avenues for growth in niche and underpenetrated segments.

Financially, the deal is expected to be transformative. Industry analysts project that the combined entity could witness substantial revenue growth and improved operational scale in the coming years. While Organon carries a notable debt burden, Sun Pharma has indicated plans to manage financing through a mix of internal accruals and external funding, with a long-term focus on balance sheet stability.

The acquisition highlights a broader trend of Indian pharmaceutical companies expanding globally through strategic investments. For Sun Pharma, this deal represents a decisive step toward evolving into a leading global pharmaceutical powerhouse with a stronger presence in innovation-driven and specialty healthcare markets.

Shares of Sun Pharmaceutical Industries on the NSE are expected to remain highly active in May following its announcement to acquire U.S.-based Organon & Co. for $11.75 billion (approximately ₹97,000 crore), marking one of the largest overseas acquisitions by an Indian pharma company. The stock initially reacted strongly to the news, rising about 7%–9% in a single session, after earlier volatile movement where it had declined around 3%–5% during deal speculation due to concerns over valuation and leverage.

The transaction is expected to significantly reshape Sun Pharma’s global scale, with Organon bringing in annual revenues of roughly $6 billion and a debt load of about $8.6 billion, which the company will absorb as part of the acquisition structure. Market participants are closely watching how this leverage will impact Sun Pharma’s balance sheet in the near term, even as the deal is projected to potentially expand the combined revenue base substantially over the next few years.

For May trading on the NSE, the stock is likely to remain volatile within a broad range, with analysts expecting periods of consolidation after the initial rally. While bullish sentiment is supported by expectations of long-term revenue diversification and global market expansion, short-term price movement will depend on investor comfort with the size of the deal, integration risks, and financing strategy. Overall, the outlook remains a mix of strong long-term optimism against near-term cautious trading behavior.

Sun Pharma’s share price on the NSE in May is expected to move in a broad range of about -10% to +20%, with a more likely outcome of sideways to mildly positive performance around 0% to +12%, as the initial rally from the Organon acquisition announcement is followed by profit booking and consolidation.

Disclaimer: The price movements mentioned are only probabilistic estimates based on current market conditions and news flow, and buying or selling of shares is entirely at the investor’s own risk.